Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705845 | 0.78 | HDAC6 (0.45) | HDAC6HDAC1KMT2A | |
| SCHEMBL16086393 | 0.78 | POLB (0.49) | HDAC6HDAC1KMT2A | |
| SCHEMBL15201129 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL6429729 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL3991501 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL20503304 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL3139122 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL20503303 | 0.74 | KMT2A (0.56) | HDAC6HDAC1KMT2A | |
| SCHEMBL1707150 | 0.74 | TSHR (0.48) | KMT2A | |
| SCHEMBL5130352 | 0.72 | TSHR (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | HDAC6 2104/4885HDAC1 1901/4885KMT2A 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.